MicroRNA Profiling in Prostate Cancer - The Diagnostic Potential of Urinary miR-205 and miR-214

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Srivastava, Anvesha ^a   Goldberger, Helle ^a   Dimtchev, Alexander ^a   Ramalinga, Malathi ^a   Chijioke, Juliet ^a   Marian, Catalin ^b   Oermann, Eric K ^c   Uhm, Sunghae ^c   Kim, Joy S ^c   Chen, Leonard N ^c   Li, Xin ^c   Berry, Deborah L ^c   Kallakury, Bhaskar V S ^c   Chauhan, Subhash C ^d   Collins, Sean P ^c   Suy, Simeng ^c   Kumar, Deepak ^a,c  

^a UNIVERSITY OF THE DISTRICT OF COLUMBIA   (United States)

^b VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c GEORGETOWN UNIVERSITY   (United States)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MICRORNA 205; MICRORNA 214; MICRORNA 221; MICRORNA 99B; UNCLASSIFIED DRUG; MICRORNA; MIRN205 MICRORNA, HUMAN; MIRN214 MICRORNA, HUMAN; MIRN221 MICRORNA, HUMAN; RNA; TUMOR MARKER;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ETHNICITY; EUROPEAN AMERICAN; HUMAN; MALE; MICROARRAY ANALYSIS; POLYMERASE CHAIN REACTION; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS; CAUCASIAN; CLINICAL TRIAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; MIDDLE AGED; PATHOLOGY; PROSTATIC NEOPLASMS; UNITED STATES; URINE;

AFRICAN AMERICANS; AGED; DOWN-REGULATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PROSTATIC NEOPLASMS; RNA, NEOPLASM; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 84886004768     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076994     Document Type: Article

References (82)

1. Siegel R, Naishadham D, Jemal A, (2013) Cancer statistics, 2013. CA: A Cancer Journal for Clinicians 63: 11-30.
2. Wu Z, Sun H, Zeng W, He J, Mao X, (2012) Upregulation of MircoRNA-370 Induces Proliferation in Human Prostate Cancer Cells by Downregulating the Transcription Factor FOXO1. PLoS One 7: e45825.
3. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, et al. (1991) Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer. New England Journal of Medicine 324: 1156-1161.
4. Lilja H, Ulmert D, Vickers AJ, (2008) Prostate- specific antigen and prostate cancer: prediction, detection and monitoring. Nature Reviews- Cancer 8: 268-278.
5. Backer H, (1999) Prostate Cancer Screening: Exploring the Debate. The Permanente Journal 3: 30-40.
6. Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, et al. (2009) Mortality Results from a Randomized Prostate-Cancer Screening Trial. New England Journal of Medicine 360: 1310-1319.
7. Schröder FH, Hugosson J, Roobol MJ, Tammela TLJ, Ciatto S, et al. (2009) Screening and Prostate-Cancer Mortality in a Randomized European Study. New England Journal of Medicine 360: 1320-1328.
8. Djulbegovic M, Beyth RJ, Neuberger MM, Stoffs TL, Vieweg J, et al. (2010) Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ 341.
9. Jansen FH, van Schaik RHN, Kurstjens J, Horninger W, Klocker H, et al. (2010) Prostate-Specific Antigen (PSA) Isoform p2PSA in Combination with Total PSA and Free PSA Improves Diagnostic Accuracy in Prostate Cancer Detection. European Urology 57: 921-927.
10. Shariat SF, Semjonow A, Lilja H, Savage C, Vickers AJ, et al. (2011) Tumor markers in prostate cancer I: blood- based markers. Acta Oncologica (Formerly: Acta Radiologica Oncology) 50: 61.
11. Bartel DP, (2004) MicroRNAs: Genomics, Biogenesis, Mechanism, and Function. Cell 116: 281-297.
12. Ambros V, (2004) The functions of animal microRNAs. Nature 431: 350-355.
13. Lewis BP, Burge CB, Bartel DP, (2005) Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA Targets. Cell 120: 15-20.
14. Friedman RC, Farh KK-H, Burge CB, Bartel DP, (2009) Most mammalian mRNAs are conserved targets of microRNAs. Genome Research 19: 92-105.
15. Nguyen HCN, Xie W, Yang M, Hsieh C-L, Drouin S, et al. (2013) Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer. Prostate 73: 346-354.
16. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, et al. (2005) MicroRNA expression profiles classify human cancers. Nature 435: 834-838.
17. Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, et al. (2005) Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 25: 2537-2545.
18. Esquela-Kerscher A, Slack F, (2006) Oncomirs- microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269.
19. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, et al. (2006) Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9: 189-198.
20. Wang S, Wang L, Zhu T, Gao X, Li J, et al. (2010) Improvement of tissue preparation for laser capture microdissection: application for cell type-specific miRNA expression profiling in colorectal tumors. BMC Genomics 11: 163.
21. Davis S, Meltzer PS, (2007) GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor. Bioinformatics 23: 1846-1847.
22. Garcia DM, Baek D, Shin C, Bell GW, Grimson A, et al. (2011) Weak seed-pairing stability and high target-site abundance decrease the proficiency of lsy-6 and other microRNAs. Nat Struct Mol Biol 18: 1139-1146.
23. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, et al. (2005) Combinatorial microRNA target predictions. Nat Genet 37: 495-500.
24. Wang X, (2008) miRDB: a microRNA target prediction and functional annotation database with a wiki interface. RNA 14: 1012-1017.
25. Hsu SD, Lin FM, Wu WY, Liang C, Huang WC, et al. (2011) miRTarBase: a database curates experimentally validated microRNA-target interactions. Nucleic Acids Res 39: D163-169.
26. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
27. Wettenhall JM, Smyth GK, (2004) limmaGUI: a graphical user interface for linear modeling of microarray data. Bioinformatics 20: 3705-3706.
28. Verhoeven KJF, Simonsen KL, McIntyre LM, (2005) Implementing false discovery rate control: increasing your power. Oikos 108: 643-647.
29. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, et al. (2009) The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments. Clinical Chemistry 55: 611-622.
30. Gidlof O, Smith JG, Miyazu K, Gilje P, Spencer A, et al. (2013) Circulating cardio-enriched microRNAs are associated with long-term prognosis following myocardial infarction. BMC Cardiovascular Disorders 13: 12.
31. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, et al. (2010) Integrative Genomic Profiling of Human Prostate Cancer. Cancer Cell 18: 11-22.
32. Lin P-C, Chiu Y-L, Banerjee S, Park K, Mosquera JM, et al. (2013) Epigenetic Repression of miR-31 Disrupts Androgen Receptor Homeostasis and Contributes to Prostate Cancer Progression. Cancer Research 73: 1232-1244.
33. Schaefer A, Jung M, Mollenkopf H-J, Wagner I, Stephan C, et al. (2010) Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. International Journal of Cancer 126: 1166-1176.
34. Gandellini P, Folini M, Longoni N, Pennati M, Binda M, et al. (2009) miR-205 Exerts Tumor-Suppressive Functions in Human Prostate through Down-regulation of Protein Kinase CÎμ. Cancer Research 69: 2287-2295.
35. Hulf T, Sibbritt T, Wiklund E, Bert S, Strbenac D, et al. (2011) Discovery pipeline for epigenetically deregulated miRNAs in cancer: integration of primary miRNA transcription. BMC Genomics 12: 54.
36. Verdoodt B, Neid M, Vogt M, Kuhn V, Liffers ST, et al. (2013) MicroRNA-205, a novel regulator of the anti-apoptotic protein Bcl2, is downregulated in prostate cancer. Int J Oncol 43: 307-314.
37. Hagman Z, Haflidadottir BS, Ceder JA, Larne O, Bjartell A, et al. (2013) miR-205 negatively regulates the androgen receptor and is associated with adverse outcome of prostate cancer patients. Br J Cancer 108: 1668-1676.
38. Tucci P, Agostini M, Grespi F, Markert EK, Terrinoni A, et al. (2012) Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proceedings of the National Academy of Sciences 109: 15312-15317.
39. Puhr M, Hoefer J, Schafer G, Erb HHH, Oh SJ, et al. (2012) Epithelial-to-Mesenchymal Transition Leads to Docetaxel Resistance in Prostate Cancer and Is Mediated by Reduced Expression of miR-200c and miR-205. The American Journal of Pathology 181: 2188-2201.
40. Hulf T, Sibbritt T, Wiklund ED, Patterson K, Song JZ, et al. (2013) Epigenetic-induced repression of microRNA-205 is associated with MED1 activation and a poorer prognosis in localized prostate cancer. Oncogene 32: 2891-2899.
41. Bhatnagar N, Li X, Padi SKR, Zhang Q, Tang MS, et al. (2010) Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Cell Death and Dis 1: e105.
42. Boll K, Reiche K, Kasack K, Morbt N, Kretzschmar AK, et al. (2013) MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma. Oncogene 32: 277-285.
43. Coppola V, De Maria R, Bonci D, (2010) MicroRNAs and prostate cancer. Endocrine-Related Cancer 17: F1-F17.
44. Childs G, Fazzari M, Kung G, Kawachi N, Brandwein-Gensler M, et al. (2009) Low-Level Expression of MicroRNAs let-7d and miR-205 Are Prognostic Markers of Head and Neck Squamous Cell Carcinoma. The American Journal of Pathology 174: 736-745.
45. Wiklund ED, Bramsen JB, Hulf T, Dyrskjøt L, Ramanathan R, et al. (2011) Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. International Journal of Cancer 128: 1327-1334.
46. Wang F, Liu M, Li X, Tang H, (2013) MiR-214 reduces cell survival and enhances cisplatin-induced cytotoxicity via down-regulation of Bcl2l2 in cervical cancer cells. FEBS Letters 587: 488-495.
47. Vaksman O, Stavnes HT, Kærn J, Trope CG, Davidson B, et al. (2011) miRNA profiling along tumour progression in ovarian carcinoma. Journal of Cellular and Molecular Medicine 15: 1593-1602.
48. Mitra AK, Zillhardt M, Hua Y, Tiwari P, Murmann AE, et al. (2012) MicroRNAs Reprogram Normal Fibroblasts into Cancer-Associated Fibroblasts in Ovarian Cancer. Cancer Discovery 2: 1100-1108.
49. Xia H, Ooi LLPJ, Hui KM, (2012) MiR-214 Targets β-Catenin Pathway to Suppress Invasion, Stem-Like Traits and Recurrence of Human Hepatocellular Carcinoma. PLoS ONE 7: e44206.
50. Wang X, Chen J, Li F, Lin Y, Zhang X, et al. (2012) MiR-214 inhibits cell growth in hepatocellular carcinoma through suppression of β-catenin. Biochemical and Biophysical Research Communications 428: 525-531.
51. Shih T-C, Tien Y-J, Wen C-J, Yeh T-S, Yu M-C, et al. (2012) MicroRNA-214 downregulation contributes to tumor angiogenesis by inducing secretion of the hepatoma-derived growth factor in human hepatoma. Journal of Hepatology 57: 584-591.
52. Li B, Han Q, Zhu Y, Yu Y, Wang J, et al. (2012) Down-regulation of miR-214 contributes to intrahepatic cholangiocarcinoma metastasis by targeting Twist. FEBS Journal 279: 2393-2398.
53. Zhang X, Ye H, Zeng C, He B, Zhang H, et al. (2010) Dysregulation of miR-15a and miR-214 in human pancreatic cancer. Journal of Hematology & Oncology 3: 46.
54. Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, et al. (2010) Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. The Lancet Oncology 11: 136-146.
55. Rong M, Chen G, Dang Y, (2013) Increased MiR-221 expression in hepatocellular carcinoma tissues and its role in enhancing cell growth and inhibiting apoptosis in vitro. BMC Cancer 13: 21.
56. Nassirpour R, Mehta PP, Baxi SM, Yin M-J, (2013) miR-221 Promotes Tumorigenesis in Human Triple Negative Breast Cancer Cells. PLoS One 8: e62170.
57. Lupini L, Bassi C, Ferracin M, Bartonicek N, D'Abundo L, et al. (2013) miR-221 affects multiple cancer pathways by modulating the level of hundreds messenger RNAs. Frontiers in Genetics 4: 64.
58. Gordanpour A, Stanimirovic A, Nam RK, Moreno CS, Sherman C, et al. (2011) miR-221 Is Down-regulated in TMPRSS2:ERG Fusion-positive Prostate Cancer. Anticancer Research 31: 403-410.
59. Gimenes-Teixeira HL, Lucena-Araujo AR, Dos Santos GA, Zanette DL, Scheucher PS, et al. (2013) Increased expression of miR-221 is associated with shorter overall survival in T-cell acute lymphoid leukemia. Exp Hematol Oncol 2: 10.
60. Spahn M, Kneitz S, Scholz C-J, Stenger N, Rüdiger T, et al. (2010) Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. International Journal of Cancer 127: 394-403.
61. Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV, et al. (2007) miR-221 and miR-222 Expression Affects the Proliferation Potential of Human Prostate Carcinoma Cell Lines by Targeting p27Kip1. Journal of Biological Chemistry 282: 23716-23724.
62. Mercatelli N, Coppola V, Bonci De, Miele F, Costantini A, et al. (2008) The Inhibition of the Highly Expressed Mir-221 and Mir-222 Impairs the Growth of Prostate Carcinoma Xenografts in Mice. PLoS One 3: e4029.
63. Sun D, Lee YS, Malhotra A, Kim HK, Matecic M, et al. (2011) miR-99 Family of MicroRNAs Suppresses the Expression of Prostate-Specific Antigen and Prostate Cancer Cell Proliferation. Cancer Research 71: 1313-1324.
64. Sun T, Wang Q, Balk S, Brown M, Lee G-SM, et al. (2009) The Role of microRNA-221 and microRNA-222 in Androgen-Independent Prostate Cancer Cell Lines. Cancer Research 69: 3356-3363.
65. Kang J, Lee SY, Kim YJ, Park JY, Kwon SJ, et al. (2012) microRNA-99b acts as a tumor suppressor in non-small cell lung cancer by directly targeting fibroblast growth factor receptor 3. Exp Ther Med 3: 149-153.
66. Hisaoka M, Matsuyama A, Nagao Y, Luan L, Kuroda T, et al. (2011) Identification of altered MicroRNA expression patterns in synovial sarcoma. Genes, Chromosomes and Cancer 50: 137-145.
67. Feber A, Xi L, Pennathur A, Gooding WE, Bandla S, et al. (2011) MicroRNA Prognostic Signature for Nodal Metastases and Survival in Esophageal Adenocarcinoma. The Annals of Thoracic Surgery 91: 1523-1530.
68. De Luca P, Moiola CP, Zalazar F, Gardner K, Vazquez ES, et al. (2013) BRCA1 and p53 regulate critical prostate cancer pathways. Prostate Cancer Prostatic Dis.
69. Chen C, Duckworth CA, Zhao Q, Pritchard DM, Rhodes JM, et al. (2013) Increased Circulation of Galectin-3 in Cancer Induces Secretion of Metastasis-Promoting Cytokines from Blood Vascular Endothelium. Clinical Cancer Research 19: 1693-1704.
70. Chen P-C, Lin T-H, Cheng H-C, Tang C-H, (2012) CCN3 increases cell motility and ICAM-1 expression in prostate cancer cells. Carcinogenesis 33: 937-945.
71. Epstein R, (2007) VEGF signaling inhibitors: More pro-apoptotic than anti-angiogenic. Cancer and Metastasis Reviews 26: 443-452.
72. Ozanne BW, Spence HJ, McGarry LC, Hennigan RF, (2006) Transcription factors control invasion: AP-1 the first among equals. Oncogene 26: 1-10.
73. Bitting RL, Armstrong AJ, (2013) Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. Endocrine-Related Cancer 20: R83-R99.
74. Burgio SL, Fabbri F, Seymour IJ, Zoli W, Amadori D, et al. (2012) Perspectives on mTOR inhibitors for castration-refractory prostate cancer. Curr Cancer Drug Targets 12: 940-949.
75. Hanke M, Hoefig K, Merz H, Feller AC, Kausch I, et al. (2010) A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urologic Oncology: Seminars and Original Investigations 28: 655-661.
76. Yamada Y, Enokida H, Kojima S, Kawakami K, Chiyomaru T, et al. (2011) MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology. Cancer Science 102: 522-529.
77. Puerta-Gil P, Garcia-Baquero R, Jia AY, Ocana S, Alvarez-Mugica M, et al. (2012) miR-143, miR-222, and miR-452 Are Useful as Tumor Stratification and Noninvasive Diagnostic Biomarkers for Bladder Cancer. The American Journal of Pathology 180: 1808-1815.
78. Nishiyama N, Arai E, Chihara Y, Fujimoto H, Hosoda F, et al. (2010) Genome-wide DNA methylation profiles in urothelial carcinomas and urothelia at the precancerous stage. Cancer Science 101: 231-240.
79. Lorenzen JM, Thum T, (2012) Circulating and Urinary microRNAs in Kidney Disease. Clinical Journal of the American Society of Nephrology 7: 1528-1533.
80. von Brandenstein M, Pandarakalam JJ, Kroon L, Loeser H, Herden J, et al. (2012) MicroRNA 15a, Inversely Correlated to PKCα, Is a Potential Marker to Differentiate between Benign and Malignant Renal Tumors in Biopsy and Urine Samples. The American Journal of Pathology 180: 1787-1797.
81. Kuner R, Brase JC, Saltmann H, Wuttig D, (2013) microRNA biomarkers in body fluids of prostate cancer patients. Methods 59: 132-137.
82. Bryant RJ, Pawlowski T, Catto JWF, Marsden G, Vessella RL, et al. (2012) Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer 106: 768-774.